title: Genetic intratumour heterogeneity in high-grade brain tumours is associated with telomere-dependent mitotic instability.
abstract: Glioblastoma multiforme (GBM) and other high-grade brain tumours are typically characterized by complex chromosome abnormalities and extensive intratumour cytogenetic heterogeneity. The mechanisms behind this diversity have been little explored. In this study, we analysed the pattern of chromosome segregation at mitosis in 20 brain tumours. We found an abnormal segregation of chromatids at mitosis through anaphase bridging (10-25% of anaphase cells) in all 10 GBMs. Anaphase bridging was also found in two medulloblastomas (7-15%), one anaplastic astrocytoma (17%) and one oligodendroglioma (6%). These tumours showed a relatively high degree of cytogenetic complexity and heterogeneity. In contrast, cell division abnormalities were not found in low-grade brain tumours with less complex karyotypes, including two pilocytic astrocytomas and two ependymomas. Further analysis of two GBMs by fluorescence in situ hybridization with telomeric repeat probes revealed excessive shortening of TTAGGG repeats, indicating dysfunctional protection of chromosome ends. In xenografts established from these GBMs, there was a gradual reduction in cytogenetic heterogeneity through successive passages as the proportion of abnormally short telomeres was reduced and the frequency of anaphase bridges decreased from >25% to 0. However, bridging could be reintroduced in late-passage xenograft cells by pharmacological induction of telomere shortening, using a small-molecule telomerase inhibitor. Telomere-dependent abnormal segregation of chromosomes at mitosis is thus a common phenomenon in high-grade brain tumours and may be one important factor behind cytogenetic intratumour diversity in GBM.
authors.affiliation: The Rausing Laboratory, Division of Neurosurgery, Lund University Hospital, Lund, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Glanz
authors.forename: J
authors.initials: J
authors.lastname: Rebetz
authors.forename: Y
authors.initials: Y
authors.lastname: Stewénius
authors.forename: A
authors.initials: A
authors.lastname: Persson
authors.forename: E
authors.initials: E
authors.lastname: Englund
authors.forename: N
authors.initials: N
authors.lastname: Mandahl
authors.forename: F
authors.initials: F
authors.lastname: Mertens
authors.forename: L G
authors.initials: LG
authors.lastname: Salford
authors.forename: B
authors.initials: B
authors.lastname: Widegren
authors.forename: X
authors.initials: X
authors.lastname: Fan
authors.forename: D
authors.initials: D
authors.lastname: Gisselsson
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000648:ultrastructure; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D002842:Chromatids / Q000235:genetics; D020090:Chromosome Segregation / Q000502:physiology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D008875:Middle Aged; D009368:Neoplasm Transplantation; D010641:Phenotype; D012854:Sister Chromatid Exchange / Q000235:genetics; D008941:Spindle Apparatus / Q000473:pathology* / Q000648:ultrastructure; D019098:Telomerase / Q000037:antagonists & inhibitors / Q000378:metabolism; D016615:Telomere / Q000473:pathology* / Q000648:ultrastructure; D014183:Transplantation, Heterologous
chemical_list: D019098:Telomerase